Aeon Biopharma, Inc. · AMEX:AEON
Aeon Biopharma — Investor Presentation (March 2025)
17 slides from Aeon Biopharma's investor presentation, Mar 10, 2025
Slide 1: Corporate Presentation March 2025: PrabotulinumtoxinA
Corporate Presentation March 2025 PrabotulinumtoxinA Potential biosimilar for therapeutic indications
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and a
Slide 3: Biosimilar Pathway - Faster to Market With Broader Indication Potential
3 Biosimilar Pathway - Faster to Market With Broader Indication Potential FDA Approved Manufacturing Biosimilar Pathway Substantial Existing Evidence Next Steps & Limited IP Risk Limited Competition/Large Market Established Regulatory Pathway Pursuing the 351(k) regulatory pathway with Prabotulinumt
Slide 4: Experienced Management Team
4 Leadership team with relevant industry experience and track record of success Experienced Management Team Marc Forth Chad Oh, MD Chief Executive Officer Chief Medical Officer • 25+ years of Biopharma experience • Former US Business Lead for BOTOX® Therapeutic • 16 years at Allergan dedicated to th
Slide 5: PrabotulinumtoxinA - Same kDa Molecular Weight as Botox
5 PrabotulinumtoxinA - Same 900 kDa Molecular Weight as Botox AbbVie Inc. Merz Pharma Ipsen Group Crown Laboratories Molecular Size 900 kDa 900 kDa 150 kDa ~400 kDa 150 kDa Approved Therapeutic Indications 1. Chronic migraine 2. Overactive bladder 3. Detrusor overactivity 4. Pediatric detrusor overa
Slide 6: Biosimilar Requirements for FDA Approval
6 FDA evaluates each proposed biosimilar and advises on the extent of testing to establish biosimilarity Biosimilar Requirements for FDA Approval 1. Manufacturing facilities for therapeutics use would require separate regulatory inspection https://www.fda.gov/drugs/biosimilars/review-and-approval ht
Slide 7: Seeking Approval of PrabotulinumtoxinA as a Biosimilar to Botox
7 Potential approval for all 12 therapeutic indications - >$2.7 B in US sales in 2024 Seeking Approval of PrabotulinumtoxinA as a Biosimilar to Botox 1. https://www.fda.gov/drugs/biosimilars/review-and-approval Chronic migraine Cervical dystonia Adult upper limb spasticity Adult lower limb spasticit
Slide 8: Botox US Therapeutic Sales Continue to Show Consistent Growth
8 Continues to show consistent growth Botox US Therapeutic Sales 2021-present – 95% Share of US Market Source: AbbVie quarterly earnings reports • Current indications: Organic growth in current indications driven primarily by continued investment in disease awareness and growing patient populations
Slide 9: AEON Model Could Allow Reimbursement Based Solely on Therapeutic Pricing
9 No competitive botulinum toxin product has a separate BLA exclusively for therapeutic indications AEON Model Could Allow Reimbursement Based Solely on Therapeutic Pricing *Average selling price Value to Physician Consistent, predictable reimbursement Value to Payor Potential to offer financial inc
Slide 10: Biosimilar Market Landscape
Favorable regulatory environment Higher penetration with more recent launches Still limited competition and predictable pricing dynamics Biosimilar Market Landscape
Slide 11: More Recent Biosimilar Launches are Achieving Higher Shares
11 3 launches in 2019 achieved ~70% penetration within 3 years More Recent Biosimilar Launches are Achieving Higher Shares Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA MIDAS, IQVIA DDD, Oct 2022; IQVIA Institute, Dec 2022
Slide 12: Stronger Uptake of Biosimilars in Buy-and-Bill Markets
12 Physicians have incentive to select one product over another Stronger Uptake of Biosimilars in Buy-and-Bill Markets Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA LAAD Medical Procedures Claims, Sep 2022; US Market Access Strategy Consulting, Dec 2022.
Slide 13: Biosimilar Pricing Dynamics
13 Price discounts in the 18-50% range within 3 years of launch Biosimilar Pricing Dynamics Reproduced with permission; IQVIA “Biosimilars in the United States 2023-2027” IQVIA National Sales Perspective, US Market Access Strategy Consulting, Dec 2022.
Slide 14: Summary and Key Milestones
14 Summary and Key Milestones Key points PrabotulinumtoxinA is the most advanced 900 kDa toxin (same molecular weight as BOTOX) in development Substantial analytical characterization has been previously completed PrabotulinumtoxinA manufacturing for aesthetic indications is already FDA approved* and
Slide 15: Capitalization Overview
Do AEON BIOPHARMA Capitalization Overview
Slide 16: Capitalization & Convertible Debt Overview
16 Capitalization & Convertible Debt Overview Potential additional shares: ~10.1M Shares Outstanding1 1. As of March 5, 2025. The Company anticipates ~11.85M shares will be outstanding following the exercises of the currently outstanding Series B Warrants issued in connection with the Company’s publ
Slide 17: Thank You
Thank You